You are here: Industry Insights > Novartis

News List

Novartis sales, profits rise in first quarter on COVID-19 buying rush expresspharma
April 29, 2020
The result topped Novartis’s 2020 forecast of mid to high single-digit percentage growth for revenue and high single-digit to low double-digit growth for operating profit.
A New Indication of Secukinumab to be Approved in China! PharmaSources/Caicai
April 26, 2020
The marketing application (acceptance No. JXSS1900025) of a new indication of Novartis’ secukinumab in China has recently changed to “Under approval” and is expected to be approved soon. First approved by the NMPA for marketing in Mar. 2019, this will be
Novartis' Jakavi bests current therapy for GvHD pharmatimes
April 26, 2020
Results of the Phase III REACH2 study show that Novartis' Jakavi (ruxolitinib) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GvHD) compared to best available therapy (BAT).
Kymriah Receives FDA Regenerative Medicine Advanced Therapy Designation americanpharmaceuticalreview
April 26, 2020
Novartis announced the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah® (tisagenlecleucel).
FDA grants RMAT designation to Novartis’ Kymriah in follicular cancer pharmaceutical-technology
April 23, 2020
The US Food and Drug Administration (FDA) has awarded regenerative medicine advanced therapy (RMAT) designation to Novartis’ Kymriah (tisagenlecleucel) to treat relapsed or refractory (r/r) follicular lymphoma (FL).
Novartis’ Kymriah Gets RMAT Designation contractpharma
April 23, 2020
Investigational new indication to treat patients with relapsed or refractory follicular lymphoma.
Novartis highlights benefits of Mayzent in MS pharmatimes
April 22, 2020
New data showing the benefits of Novartis' Mayzent (siponimod) in patients with secondary progressive multiple sclerosis (SPMS) have been published in the April supplemental issue of American Academy of Neurology.
Novartis to test efficacy of old malaria drug against COVID-19 expresspharma
April 22, 2020
The company hopes to have data on its efficacy by June, a lead researcher for the trial told Reuters.
Novartis to Sponsor Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients americanpharmaceuticalreview
April 21, 2020
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19
Novartis expands ophthalmology pipeline with Amblyotech acquisition pharmaceutical-technology
April 21, 2020
Novartis has acquired US-based software startup Amblyotech, which is developing a digital treatment for amblyopia (lazy eye) that leads to vision loss in children and young adults.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page